The use of liposomes as intravitreal drug delivery system;Administration intra-vitréenne de liposomes pour la vectorisation de principes actifs

Journal Francais d'Ophtalmologie

Volumn 26, Issue 9, 2003, Pages 981-985

  Bejjani, R A ^a,b   Jeanny, J C ^a   Bochot, A ^c   Behar Cohen, F ^a,d  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b HÔTEL DIEU   (France)

^c UNIV PARIS SUD   (France)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

Drug delivery systems; Gene transfer techniques; Liposomes; Local anti infective agents; Vitreous body

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMETABOLITE; ANTIVIRUS AGENT; CYCLOSPORIN; LIPOSOME; OLIGONUCLEOTIDE; PLASMID DNA;

DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENCAPSULATION; GENE TRANSFER; REVIEW; STRUCTURE ANALYSIS;

ADMINISTRATION, TOPICAL; BIOLOGICAL AVAILABILITY; BLOOD-RETINAL BARRIER; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HALF-LIFE; HUMANS; LIPOSOMES; METABOLIC CLEARANCE RATE; VITREOUS BODY;

EID: 0345708389     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Bar-Ilan A, Neumann R. Basic considerations of ocular drug delivery systems. In: Zimmerman T, ed. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven Publishers, 1997.
2. Niesman MR. The use of liposomes as drug carriers in ophthalmology. Crit Rev Ther Drug Carrier Syst, 1992;9:1-38.
3. Desmettre T, Mordon S, Soulie S, Devoisselle JM, Weisslinger JM. Liposomes in opthalmology. Review of the literature. J Fr Ophtalmol, 1996;19:716-31.
4. Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res, 2000; 19:131-47.
5. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliver Rev, 1995;16:75-93.
6. Fiscella R, Peyman GA, Fishman PH. Duration of therapeutic levels of intravitreally injected liposome-encapsulated clindamycin in the rabbit. Can J Ophthalmol, 1987;22:307-9.
7. Metrikin DC, Anand R. Intravitreal drug administration with depot devices. Curr Opin Ophthalmol, 1994;5:21-9.
8. Kawakami S, Yamamura K, Mukai T, Nishida K, Nakamura J, Sakaeda T, et al. Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J Pharm Pharmacol, 2001;53:1157-61.
9. Cheng L, Hostetler KY, Chaidhawangul S, Gardner MF, Beadle JR, Keefe KS, et al. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest Ophthalmol Vis Sci, 2000;41:1523-32.
10. Liu KR, Peyman GA, Khoobehi B, Alkan H, Fiscella R. Intravitreal liposome-encapsulated trifluorothymidine in a rabbit model. Ophthalmology, 1987;94:1155-9.
11. Barza M, Baum J, Tremblay C, Szoka F, d'Amico DJ. Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. Am J Ophthalmol, 1985;100:259-63.
12. Stern WH, Heath TD, Lewis GP, Guerin CJ, Erickson PA, Lopez NG, Hong KL. Clearance and localization of intravitreal liposomes in the aphakic vitrectomized eye. Invest Ophthalmol Vis Sci, 1987; 28:907-11.
13. Barza M, Stuart M, Szoka F (Jr). Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci, 1987;28:893-900.
14. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, ed. Pharmacology of the eye. New York: Springer, 1984.
15. Masuda I, Matsuo T, Yasuda T, Matsuo N. Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest Ophthalmol Vis Sci, 1996;37:1914-20.
16. Hangai M, Tanihara H, Honda Y, Kaneda Y. Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest Ophthalmol Vis Sci, 1998;39:509-16.
17. Zeng S, Hu C, Wei H, Lu Y, Zhang Y, Yang J, et al. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology, 1993; 100:1640-4.
18. Fishman PH, Peyman GA, Lesar T. Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Invest Ophthalmol Vis Sci, 1986; 27:1103-6.
19. Kim EK, Kim HB. Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits. Yonsei Med J, 1990;31:308-14.
20. Wiechens B, Krausse R, Grammer JB, Neumann D, Pleyer U, Duncker GI. Clearance of liposome-incorporated ciprofloxacin after intravitreal injection in rabbit eyes. Klin Monatsbl Augenheilkd, 1998;213:284-92.
21. Kuppermann BD, Assil KK, Vuong C, Besen G, Wiley CA, De Clercq E, et al. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine for long-acting therapy of viral retinitis. J Infect Dis, 1996;173:18-23.
22. Peyman GA, Khoobehi B, Tawakol M, Schulman JA, Mortada HA, Alkan H, et al. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina, 1987;7:227-9.
23. Cheng L, Hostetler KY, Chaidhawangul S, Gardner MF, Beadle JR, Keefe KS, et al. Intravitreal toxicology and duration efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest Ophthalmol Vis Sci, 2000;41: 1523-32.
24. Peyman GA, Schulman JA, Khoobehi B, Alkan HM, Tawakol ME, Mani H. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina, 1989;9:232-6.
25. Akula SK, Ma PE, Peyman GA, Rahimy MH, Hyslop NE (Jr), et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol, 1994;78:677-80.
26. Diaz-Llopis M, Martos MJ, Espana E, Cervera M, Vila AO, Navea A, et al. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial. Doc Ophthalmol, 1992;82:297-305.
27. Peyman GA, Charles HC, Liu KR, Khoobehi B, Niesman M. Intravitreal liposome-encapsulated drugs: a preliminary human report. Int Ophthalmol, 1988;12:175-82.
28. Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther, 2000;16:511-8.
29. Gupta SK, Dhingra N, Velpandian T, Jaiswal J. Efficacy of fluconazole and liposome entrapped fluconazole for C. albicans induced experimental mycotic endophthalmitis in rabbit eyes. Acta Ophthalmol Scand, 2000;78:448-50.
30. Tremblay C, Barza M, Szoka F, Lahav M, Baum J. Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits. Invest Ophthalmol Vis Sci, 1985;26:711-8.
31. Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol, 1993;231:109-14.
32. Liu KR, Peyman GA, She SC, Niesman MR, Khoobehi B. Reduced toxicity of intravitreally injected liposome-encapsulated cytarabine. Ophthalmic Surg, 1989;20:358-61.
33. Joondeph BC, Peyman GA, Khoobehi B, Yue BY. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg, 1988;19:252-6.
34. Fishman P, Peyman GA, Hendricks R, Hui SL. Liposome-encapsulated 3H-5FU in rabbits. Int Ophthalmol, 1989;13:361-5.
35. Garcia-Arumi J, Pascual R, Fonseca MJ, Isart FR, Casaroli R, Mateo C, et al. Pharmacokinetics and retinal toxicity of intravitreal liposome-encapsulated 5-fluorouridine. Ophthalmologica, 1997; 211:344-50.
36. Assil KK, Hartzer M, Weinreb RN, Nehorayan M, Ward T, Blumenkranz M. Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci, 1991;32:2891-7.
37. Gariano RF, Assil KK, Wiley CA, Munguia D, Weinreb RN, Freeman WR. Retinal toxicity of the antimetabolite 5-fluorouridine 5′-monophosphate administered intravitreally using multivesicular liposomes. Retina, 1994;14:75-80.
38. Heath TD, Lopez NG, Lewis GP, Stern WH. Antiproliferative and anticontractile effects of liposome encapsulated fluoroorotate. Invest Ophthalmol Vis Sci, 1987;28:1365-72.
39. Alghadyan AA, Peyman GA, Khoobehi B, Milner S, Liu KR. Liposome-bound cyclosporine: clearance after intravitreal injection. Int Ophthalmol, 1988;12:109-12.
40. Alghadyan AA, Peyman GA, Khoobehi B, Liu KR. Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int Ophthalmol, 1988;12:105-7.
41. Bochot A, Fattal E, Boutet V, Deverre JR, Jeanny JC, Chacun H, Couvreur P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci, 2002;43:253-9.
42. Hangai M, Kaneda Y, Tanihara H, Honda Y. In vivo gene transfer into the retina mediated by a novel liposome system. Invest Ophthalmol Vis Sci, 1996;37: 2678-85.
43. Otsuji T, Ogata N, Takahashi K, Matsushima M, Uyama M, Kaneda Y. In vivo gene transfer into choroidal neovascularization by the HVJ liposome method. Graefes Arch Clin Exp Ophthalmol, 2000;238:191-9.
44. Babizhaev MA, Brikman IV, Deev AI. Cataract induction by products of lipid peroxidation. Biofizika, 1987;32:121-4.
45. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration. J Int Assoc Physicians AIDS Care, 1996;2:50-7.
46. DOXIL approved by FDA. AIDS Patient Care, 1995;9:306.